Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis Clinical research trials and Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis. Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis clinical trial. Human subjects often get the best healthcare possible for their Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "D" Clinical Trials Conditions > Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis

Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis



Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis

For Condition: Multiple Sclerosis
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , University of Pennsylvania
Synopsis: OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization transfer ratio histogram parameters, and correlate these measurements with clinical measures of disability in patients with multiple sclerosis. II. Measure the quantity of whole brain N-acetylaspartate in patients with multiple sclerosis and compare these values to those from age matched controls. III. Determine the correlation between specific neuropsychological tests which assess global cognitive functioning and the quantitative measurements taken in these patients in this study.
Details: PROTOCOL OUTLINE: Patients undergo magnetic resonance imaging and spectroscopy with standard gadolinium contrast followed by neuropsychological testing every 6 months for 5 years. An equal number of age and sex matched healthy patients act as a control group and undergo magnetic resonance imaging and spectroscopy without standard gadolinium contrast every 6 months for 5 years.
Eligibility:
Study Type:  Observational, Screening
Minimum Age/Maximum Age: 20 Years/70 Years
Genders: Both
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of multiple sclerosis Relapsing-remitting defined as 2 exacerbations and a worsening of neurologic function over 1 day followed by at least 30 days of no progression OR Secondary-progressive defined as increase of at least 1.0 unit on Expanded Disability Status Scale (EDSS) in past 2 years with or without exacerbations --Prior/Concurrent Therapy-- - Biologic therapy: Prior interferon beta 1A, 1B, or glatiramer acetate No concurrent interferon beta 1A, 1B, or glatiramer acetate - Endocrine therapy: Concurrent oral and IV corticosteroids allowed --Patient Characteristics-- - Performance status: EDSS no greater than 7.0 - Hematopoietic: No hematologic dysfunction including hemolytic anemia - Hepatic: No hepatic dysfunction - Renal: No renal dysfunction - Cardiovascular: No cardiac pacemaker - Other: Not pregnant or nursing Negative pregnancy test No intracranial clips, metal implants, or external clips within 10 mm of head No metal in eyes No known gadolinium texaphyrin allergy No known claustrophobia
Total Enrollment: 100

Location and Contact Information:

Overall Study Official:
RobertGrossman,  Study Chair,  New York University School of Medicine

New York University Medical Center *Recruiting*
New York City,  New York,  10016
United States
Recruiting Lois  Mannon 212-263-3783


Additional Information:
Study ID Numbers:  199/15245;  UPSM-NS-29029,UPSM-070300,UPSM-704-0
Study Start Date: April 1999
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006060

Other Multiple Sclerosis Studies:
1. A study to evaluate the preliminary efficacy pharmacokinetics and immunogenicity of BMS-188667 administered to subjects with relapsing-remitting multiple sclerosis

2. Safety and Efficacy of Natalizumab in Combination with Avonex in the Treatment of Multiple Sclerosis

3. Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

4. Improving Memory in Patients with Multiple Sclerosis

5. Combination Therapy with Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

Related Studies:

Other Multiple Sclerosis Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
Modify your Search

  Other Multiple Sclerosis Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103